What is immunotherapy and does it work for Colorectal Cancer

Understanding Immunotherapy for Colorectal Cancer

What Is Immunotherapy?

Immunotherapy is a type of cancer treatment that works differently than traditional chemotherapy. Instead of directly poisoning cancer cells, immunotherapy trains and activates your own immune system to recognize and attack cancer cells.

Think of it this way: Your immune system normally protects you from infections like bacteria and viruses. Cancer cells are clever at hiding from this defense system. Immunotherapy essentially removes the "disguise" cancer uses and teaches your immune cells to see cancer as an enemy that needs to be destroyed.

How It Works

According to the medical literature, immunotherapy works by:

1. Finding what's different about the tumor - Cancer cells often turn on genes that are normally turned off, or turn up the volume on genes that are normally turned down
2. Unleashing T cells - These are immune cells that can kill cancer cells, but cancer often puts "brakes" on them
3. Creating lasting immune memory - Unlike some drugs that stop working after a few months, a successful immune response can create long-term protection

---

Does Immunotherapy Work for Colorectal Cancer?

The answer is: It depends on specific characteristics of your cancer.

The Current Reality

Immunotherapy effectiveness in colorectal cancer varies significantly based on a key genetic feature:

For MSI-High Colorectal Cancer (about 5-15% of cases):

• ✅ Good response rates - Checkpoint inhibitors like Keytruda (pembrolizumab) show meaningful benefit
• These cancers have many mutations, making them more "visible" to the immune system
• According to NCCN Guidelines, MSI-high colorectal cancer is an FDA-approved indication for checkpoint inhibitor therapy

For MSS Colorectal Cancer (about 85-95% of cases):

• ⚠️ Limited response - Standard immunotherapy alone shows modest effectiveness (roughly 10-20% response rates)
• These cancers have fewer mutations, making them harder for the immune system to recognize
• These are sometimes called "cold tumors" because they don't naturally attract immune cells

What Makes the Difference: MSI Testing

MSI stands for "Microsatellite Instability" - it's a measure of how many mutations your cancer has. According to the CancerPatientLab webinar "How MSI and Other Tests Can Guide Immunotherapies for Cancer Treatment," testing for MSI or DNA mismatch repair deficiency is recommended for colorectal cancer patients because it directly guides treatment decisions.

---

Current Treatment Approaches for Colorectal Cancer

FDA-Approved Immunotherapies

According to NCCN Guidelines and recent FDA approvals:

Checkpoint Inhibitors (for MSI-high disease):

• Keytruda (pembrolizumab)
• Opdivo (nivolumab)
• Tecentriq (atezolizumab)
• Jemperli (dostarlimab)

These work by blocking "brakes" on your immune system, allowing T cells to attack cancer more effectively.

Emerging Approaches for MSS (Standard) Colorectal Cancer

Since standard immunotherapy alone doesn't work well for most colorectal cancers, researchers are exploring combination strategies:

1. Immunotherapy + Radiation - Early research suggests combining checkpoint inhibitors with radiation therapy may help "turn cold tumors into hot tumors" by making cancer cells more visible to the immune system

2. Immunotherapy + Other Drugs - Combining checkpoint inhibitors with targeted therapies or other immune-boosting drugs to improve response rates

3. Clinical Trials - Multiple trials are underway testing new combinations and approaches specifically for MSS colorectal cancer

---

Important Questions to Ask Your Oncologist

If you have colorectal cancer and are considering immunotherapy:

1. "Has my tumor been tested for MSI status or mismatch repair deficiency?" - This test is essential for determining if immunotherapy is appropriate for you

2. "Based on my specific test results, what immunotherapy options are recommended for my situation?"

3. "Are there clinical trials available that might be appropriate for my cancer type and stage?" - This is especially important if you have MSS disease, as newer combination approaches are being studied

4. "What are the potential side effects of immunotherapy, and how would they be managed?" - Immunotherapy side effects differ from chemotherapy and can include fatigue, rashes, and immune-related inflammation

5. "If immunotherapy alone isn't recommended, what combination approaches might be considered?"

---

The Bottom Line

Immunotherapy can be very effective for colorectal cancer patients with MSI-high disease, and it's now a standard treatment option for this group. However, for the majority of colorectal cancer patients with MSS disease, immunotherapy alone has limited effectiveness—though researchers are actively working on combination strategies to improve outcomes.

The key is getting the right test (MSI testing) to understand your specific cancer's characteristics, then working with your oncology team to determine the best treatment approach for YOUR situation.

According to the NCCN Guidelines for Colorectal Cancer, MSI/mismatch repair testing should be performed on all newly diagnosed colorectal cancers to guide treatment decisions.

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.